We are currently discussing potentially deleting clause 2 of Bill C-393 and restoring section 21.02, as drafted in the current Act, and thereby bringing all the definitions back in. However, Mr. Garneau's intention, in amending the definition of “pharmaceutical product” through amendment LIB-1, was to ensure that it would be appropriate, given the amendments we have just passed, and thereby to amend the schedules.
I'm just wondering whether, by retaining the definitions as they appear in the current Act, the definition of “pharmaceutical product” will still be comprehensible and correct.